Brought to you by 
Apeiron, Evotec, Sanofi team up on cancer immunotherapies
08 Jan 2018
Executive Summary
A few days after teaming up in a diabetes deal, Evotec AG and Sanofi signed a new agreement, this time involving Apeiron Biologics AG and focusing on cancer immunotherapies.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
Deal Status
- Final
Deal Type
-
Alliance
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com